Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in two main areas, cancer and infectious disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.


Redx Pharma Plc REDX: AIM First day of trading 27/03/2015



http://redxpharma.com/

liverpoolecho.co.uk/news/business/redx-potential-treatment-hospital-superbug

Half Yearly Report
RNS
RNS Number : 7351Q
Redx Pharma plc
22 June 2015



AIM: REDX





REDX PHARMA PLC

("Redx" or the "Company" or "Group")



Redx (AIM: REDX), the drug discovery and development company, is pleased to announce its maiden unaudited results for the six months ended 31 March 2015.



HIGHLIGHTS



· Successful admission to AIM and £15m (gross) share placing on 27 March 2015



· Continued strong progress with drug discovery programs with a further program having achieved pre-clinical proof of concept:



Oncology pipeline

- first development candidate selected in SMO program for skin cancer

- in vivo proof of concept secured in BTK and cFMS programs



Post-period

- in vivo proof of concept established in Porcupine program

- development candidate selected in BTK program



Anti-infectives pipeline

- continued expansion of novel lead series in MRSA program



Post-period

- development candidate selected in MRSA program



· Launch of immunology subsidiary in May 2015 - focused on developing new therapies for disorders of the immune system



· H1 financial results in line with management expectations:

- net cash at 31 March 2015: £13.8m (H1 2014: £2.8m)

- comprehensive loss of £3.2m (H1 2014: £1.6m)



· Outlook remains positive



Neil Murray, Chief Executive of Redx Pharma plc, said:



"I am delighted with the progress Redx has made over the six month period and subsequent to the period end, both in terms of our drug discovery programs and corporately. We already have an extensive pipeline of potentially best-in-class drug therapies across cancer and anti-infectives, and over the last nine months have identified a further two drug development candidates. These include our first drug development candidate designed to tackle MRSA, the bacterium which causes potentially lethal infections in humans, which is a significant milestone for our commercial partnership with the NHS.



The launch of our third subsidiary, Redx Immunology, in May 2015, which has synergies with our existing immuno-oncology programs, is an exciting development. We expect to generate additional pipeline assets from its research activities and further partnering and licencing deals in due course.



I remain very optimistic about the opportunities available to us and Redx's admission to AIM and share placing at the end of March will help to support our ambitious plans for our ongoing development."

Cancer Research Collaboration
RNS
RNS Number : 9154X
Redx Pharma plc
03 September 2015





3 September 2015

AIM: REDX





Redx Pharma Plc



("Redx" or the "Company" or "Group")



Cancer research collaboration

with

Horizon Discovery Group plc



Redx, the drug discovery and development company, is pleased to announce a cancer research collaboration with Horizon Discovery Group plc, ("Horizon"), the international life science group.

The collaboration will focus on Redx's existing pan-RAF inhibitor program, which is focused on colorectal cancer, the fourth most common cancer and the second most common cause of cancer death in the UK.



Redx's pan-RAF inhibitor program has identified next generation novel small molecule inhibitors of RAF kinases as potential treatments for colorectal and other potential cancers. These next generation pan-Raf inhibitors have been designed to overcome resistance mechanisms seen with first generation Raf inhibitors in colorectal cancer. As part of the collaboration, Horizon will deploy its proprietary gene editing, cell line and drug discovery technology platforms and know how to help explore the mode of action of Redx's pan-RAF inhibitors and support the Company as it seeks to move this rare class of compounds towards licensing.



Under the terms of the agreement, Redx and Horizon will bear costs proportionately to respective research activities and have agreed a revenue share for any successful out-licensing.



Neil Murray, Chief Executive of Redx, commented:



"Our pan-RAF inhibitor program is dealing with novel biology and is at a very interesting point. Our partnership with Horizon will enable us to detail at molecular level the effects of our pan-RAF inhibitors and help to progress this very promising program as we seek to secure a license partner for this asset."



Dr. Darrin M. Disley, Chief Executive Officer of Horizon, commented:



"We are delighted to be able to support Redx with our proprietary technology platforms as they move towards securing a licensing agreement for these novel assets."

Trading Update
RNS
RNS Number : 8229A
Redx Pharma plc
01 October 2015



REDX PHARMA PLC

("Redx" or "the Group")

Year-end trading update

Redx, the drug discovery and development company, today announces a trading update for the financial year ended 30 September 2015.

The Board is pleased to report that Redx has continued to make good progress over the second half of the financial year and that the Group's expenditure remains in line with budgets. Total operating income for the financial year is anticipated to be £2.8 million (six months to 31 March 2015: £2.0 million). The Group's cash balance at the year-end is expected to be approximately £9.4 million.

The Group remains in encouraging discussions with a number of parties regarding further commercial collaborations. These discussions are at varying stages and involve a number of different Redx programs. In addition to the collaboration deal with Horizon, announced in September, the Board remains confident of securing further commercial agreements in due course.

Both Redx's oncology and anti-infectives research programs have continued to progress well. In particular, within oncology, we are pleased to announce that a second in vivo proof of concept candidate was established in our Porcupine program in the second half. As previously reported, within anti-infectives, a new compound designed to tackle MRSA began pre-clinical testing in the second half and this is advancing well. The Redx immunology subsidiary, launched in May and supported by £4.2 million of Regional Growth Fund grant, is focused on developing new therapies for disorders of the immune system. It has completed the recruitment of key personnel and identified its initial research areas. This new subsidiary has synergies with Redx's oncology activities and gives the Group an enhanced presence in an exciting area of research with strong commercial appeal.

The Board looks forward to reporting on further progress and expects to announce the Group's results for the year ended 30 September 2015 in mid-January 2016.



For further information, please contact:

/redx-pharma-welcomes-report-on-antimicrobial-resistance

Re: Porcupine inhibitor and cancer immunotherapy
RNS
RNS Number : 1362K
Redx Pharma plc
19 September 2016
 
 
AIM: REDX
 
 REDX PHARMA PLC
("Redx" or "the Company")
 
Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy
 
Redx, the drug development company, is pleased to confirm that its lead cancer treatment, the Porcupine inhibitor (RXC004), has a potential role in cancer immunotherapy.  Redx scientists have demonstrated that the Porcupine inhibitor could have a crucial role in improving the immune system response of some cancer patients when used in combination with an existing immunotherapy, anti-programmed cell death-1 (anti-PD-1).
 
Anti-PD-1 therapy activates the immune system to recognise and attack tumours. While treatment with PD-1 inhibitors, also known as Checkpoint inhibitors, is a significant breakthrough in cancer treatment, not all patients respond.
 
Redx has been testing a combination therapy that uses both the Porcupine inhibitor RXC004 and an anti-PD-1 antibody in a cancer model. The data demonstrates that the combination therapy significantly improves the ratio of favourable T-cells, which attack tumours, to the immunosuppressive T-cells that allow tumours to grow unrecognised, when compared to only using an anti-PD-1 therapy. This suggests that a combination therapy could potentially improve patient response rates.
 
Redx's novel, potent small molecule Porcupine inhibitor has already shown, in disease models, that it has potential as a stand-alone therapy for difficult to treat cancers, such as pancreatic cancer.
 
As previously reported, first-in-human studies for the Porcupine inhibitor, initially as a stand-alone therapy, are expected to commence early in 2017. In addition, Redx is now evaluating opportunities for combination therapies.
Neil Murray, CEO of Redx, commented:
 
"The results so far from our Porcupine inhibitor, RXC004, have been very impressive, with important implications for difficult to treat cancers, such as pancreatic cancer.
 
Over the past few years, significant progress has been made in harnessing the ability of the immune system to attack cancer. We are very pleased that our new findings confirm that our lead cancer treatment, the Porcupine inhibitor RXC004, now also has a potentially crucial role in enhancing existing cancer immunotherapy treatments.
 
Our Porcupine program has progressed from concept to moving towards first-in-human clinical trials in a little under three years, which is a remarkable achievement and evidence of our commercially disciplined approach and outstanding scientific capabilities."

Redx notes breakthrough antibiotic compounds
StockMarketWire.com
Redx has announced the discovery of a series of compounds that have the potential to create the first novel class of broad-spectrum antibiotics in 30 years.

As previously announced, Redx scientists have identified novel bacterial topoisomerase inhibitors that work as antibiotics against drug resistant Gram-negative bacteria.

In vivo testing has now confirmed that Redx has discovered a series of compounds that are highly effective against drug resistant strains of Gram-negative bacteria.

This could have important implications for drug resistant infections such as E. coli and Pseudomonas, which are responsible for critical illnesses such as pneumonia, blood poisoning, and urinary tract and abdominal infections.

In the pre-clinical study, Redx achieved a significant decrease in bacterial infection levels against a multi-drug resistant Gram-negative bacterial strain when compared with tigecycline, a current drug-of-last-resort used in treating antibiotic resistant bacteria.

The Board believes that Redx's compounds could therefore result in the development of a first-in-class treatment in an urgent area of high unmet medical need. Redx will be progressing these compounds with the objective of selecting an optimal lead compound.

Drug-resistant infections are already responsible for more than half a million deaths globally each year and this number is expected to increase.

Of these drug-resistant infections, those caused by Gram-negative bacteria are even more difficult to treat than those caused by Gram-positive bacteria.

This is because Gram-negative bacteria have an additional outer cell membrane that is not easily penetrated by drugs and antibiotics, as well as the ability to expel drugs that do manage to cross the cell membrane. This poses a huge challenge for healthcare providers as Gram-negative bacteria are increasingly becoming resistant to most available antibiotics.

Without the development of new antibiotics that kill drug-resistant bacteria, resistant infections will result in approximately 10 million extra deaths per year and cost the global economy up to US$100 trillion by 2050, according to recent findings from the Review on Antimicrobial Resistance, a UK Government initiative.

27 Sep
Cantor...
105.00
Buy

DYOR - this is only how I see it . . . .
After a loan financial issue in 2017, the suspended shares are out of Administration following a significant drug-right sale for about $40m, which, with a Fundraising, appears to leave them with £12m cash to continue...sp 20p suggests many are wary.
There is much stuff saying good things from the Company and an "independent Report" from Hardman & Co who write these for a living.... however, H won't supply a printed copy...just refer to their Website... which is a fussy alternative IMHO. The Company cannot be contacted - maybe they are having Xmas cheer-up party, or this may be reluctance to provide printed Reports ( just out - see RNS ).

What I do see is that their list of Drug-programme is far short of anything entered Ph1 -which is the most basic...=It doesn't kill healthy patients ( DYOR ). Of course profitable-drugs don't come from thin air, but I'm just not convinced they are discovering much of value to Investors. Maybe they'll be shouting from Rooftops at the next Giddy-go Exhibition, where there is much back-slapping by Execs who are making a gd living already.

Therefore.... the route to lute... may be somewhat long, er IMHO.
Redx (AIM) sp Fell 8% today, currently ~20p